Kelun Highlights First-Line Plans For Merck-Partnered Trop2 ADC

 
• By Dexter Jie Yan

To differentiate from Daiichi Sankyo/AstraZeneca's Dato-DXd, Kelun and Merck & Co. are targeting the first-line treatment of EGFR wild-type NSCLC with a combination of their antibody-drug conjugate SKB-264 (MK-2870) with an anti-PD-1 antibody. Additionally, Kelun as the sole sponsor is advancing a Phase III study of the ADC as a monotherapy for second-line EGFR inhibitor-failed NSCLC.

first line treatment
1L treatment of EGFR-wild type NSCLC takes center stage in Kelun/Merck's plan for Trop2-targeting ADC • Source: Shutterstock

More from China

More from Focus On Asia